| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 19, 2024 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 19, 2024 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company" or "Adagio")), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced, today provided business updates for third quarter ended September 30, 2024. Recent Business Highlights: Reported total company revenue of $185 thousand in the third quarter of 2024, compared to $41 thousand in the third quarter of 2023. In September 2024, secured CMS coverage (Category B) of the vCLAS™ ultra-low temperature cryoablation catheter as a part of FULCRUM-VT Pivotal IDE study for treatment of drug-resistant ventricular tachycardia (VT) in patients with structural heart disease. In October
Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company")), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that its CEO & President, Olav Bergheim, will present at the Stifel 2024 Healthcare Conference on Monday, November 18, at 9:45 a.m. Eastern Time in New York, NY at the Lotte New York Palace Hotel. A live audio webcast and replay of the presentation may be accessed on the "Investors" section of the company's website at: https://www.adagiomedical.com/. About Adagio Medical Adagio Medical is an early commercial stage medical device company located in Laguna Hills, California focusing on developing innovative cryoablation tec
Adagio Medical Holdings, Inc. (NASDAQ:ADGM, "Adagio Medical", "Adagio" or the "Company"))), a leading innovator in catheter ablation technologies, today announced the completion of the first procedures in FULCRUM-VT U.S. Food and Drug Administration (FDA) Pivotal IDE study of Adagio's VT Cryoablation System. Procedures were performed by Professor William G. Stevenson, MD, at Vanderbilt University Medical Center in Nashville, TN and Dr. J. David Burkhardt at Texas Cardiac Arrhythmias Institute (TCAI) at Austin, TX. FULCRUM-VT (Feasibility of Ultra-Low Temperature Cryoablation in Recurring Monomorphic Ventricular Tachycardia, NCT05675865) is a prospective, multi-center, open-label, single-ar
424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)
424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)
10-Q - Adagio Medical Holdings, Inc. (0002006986) (Filer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)
SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)
SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)